Trabectedin
Breast Diseases
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the Breast Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TRASTUZUMAB Incepta Pharmaceuticals Ltd | Phase 3 | BB |
SACUBITRIL VALSARTAN Silesian Centre for Heart Diseases | Phase 4 | BB |
Olaparib AstraZeneca | Phase 2 | BB |
Vinorelbine Sun Yat-sen University | Phase 2 | BB |
Capecitabine University of Southern California | Phase 3 | B |
View all 46 →
Same molecule, other indications
Trabectedin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →